Zynteglo Funding Rejection Sets "Dangerous Precedent" For Gene Therapies In UK
Bluebird Bio Rails Against Negative Reimbursement Decision
bluebird is "shocked and disappointed" at the draft negative reimbursement decision on Zynteglo in UK but measures outlined in the NICE methods review could change fortunes of gene and cell therapies if taken forward.
